Brand-name drug
Victoza price, strengths & recalls
Brand of liraglutide (generic)
Pharmacies pay $526.51 for 6 mL of Victoza 6 mg/mL, 3 mL pen this week. The generic, liraglutide, costs pharmacies from $257.25. It is in shortage (limited availability). It has 2 recalls on record, none ongoing. Its official label last changed on November 17, 2025.
Limited availabilityBrand- Fair cash price
- $615.99
- Strengths
- 1
- Makers
- 1
- Updated
- Nov 11
Victoza price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 6 mg/mL, 3 mL pen Brand | $87.75 | $526.51 / 6 mL |
Victoza vs generic liraglutide
Generics have the same active ingredient, strength and form, and FDA requires them to work the same way. What pharmacies pay for each, same quantity:
| Strength | Brand | Generic | Brand costs |
|---|---|---|---|
| 6 mg/mL, 3 mL pen | $526.51 | $171.50 | 3.1x |
Supply status: shortages & recalls
Shortages
- Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)
- Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)Estimated shortage duration: TBD
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)Distributed by Teva
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)Estimated shortage duration: TBD
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)Distributed by Teva
- Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)
- Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)
- Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)Discontinuation of the manufacture of the drug
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Victoza
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use VICTOZA® safely and effectively. See full prescribing information for VICTOZA.VICTOZA (liraglutide) injection, for subcutaneous useInitial U.S. Approval: 2010
WARNING: RISK OF THYROID C-CELL TUMORS
•
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether VICTOZA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].
•
VICTOZA is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of VICTOZA and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with VICTOZA [see Contraindications (4), Warnings and Precautions (5.1)].
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
•
Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether VICTOZA causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).
•
VICTOZA is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors (4, 5.1).
Recent major changes (as listed on the label)
Indications and Usage (1)................................................05/2025
Warnings and Precautions
Severe Gastrointestinal Adverse Reactions (5.6) 10/2025
Pulmonary Aspiration During General Anesthesia
or Deep Sedation (5.9)................................................11/2024
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA022341 · Novo Nordisk Inc
- First approved
- January 25, 2010 (16 years ago)
- Latest approved change
- October 14, 2025
- Approved label
- PDF, Oct 15, 2025
- Generic makers
- 8 approved generic applications on the market
- Last patent listed
- July 9, 2037
Victoza questions
How much does victoza cost without insurance?
Pharmacies pay about $526.51 for 6 mL of victoza 6 mg/mL, 3 mL pen ($87.75 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $615.99. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Victoza?
Yes: liraglutide. Pharmacies pay from $257.25 for it. Compare liraglutide prices.
Is victoza in shortage?
Yes. 10 products are listed as in shortage or being discontinued (limited availability). See which ones.
Has victoza been recalled?
2 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the victoza label last change?
The official label was last updated on November 17, 2025 (version 31). See what changed.
Talk about victoza
No comments yet. Questions, tips, what worked for you - start the conversation.